Kiniksa Pharmaceuticals International PLC
KNSA
Company Profile
Business description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Contact
105 Piccadilly
Second Floor
LondonW1J 7NJ
GBRT: +44 7814319100
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
366
Stocks News & Analysis
stocks
SpaceX is scaling AI infrastructure on earth, data centers in space might be next
Our view on the first results as a publicly traded company.
stocks
Investors too optimistic about overvalued ASX share
Upgraded first-half revenue guidance at the upper end of the previously announced range.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,916.20 | 40.40 | -0.45% |
| CAC 40 | 7,921.68 | 83.19 | 1.06% |
| DAX 40 | 25,645.04 | 340.62 | 1.35% |
| Dow JONES (US) | 52,856.09 | 360.21 | 0.69% |
| FTSE 100 | 10,752.88 | 19.88 | 0.19% |
| HKSE | 22,979.95 | 671.92 | -2.84% |
| NASDAQ | 26,702.86 | 278.04 | 1.05% |
| Nikkei 225 | 63,258.24 | 1,363.00 | -2.11% |
| NZX 50 Index | 13,746.84 | 14.45 | -0.11% |
| S&P 500 | 7,757.17 | 44.60 | 0.58% |
| S&P/ASX 200 | 8,792.30 | 39.00 | -0.44% |
| SSE Composite Index | 3,664.61 | 48.41 | -1.30% |